ArticleMovement disorders : official journal of the Movement Disorder Society2022
Autopsy Validation of Progressive Supranuclear Palsy-Predominant Speech/Language Disorder Criteria.
Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Voice and Speech in Atypical Parkinsonian Disorders.Movement disorders clinical practice · 2026Review
- Progressive Supranuclear Palsy with Predominant Speech/Language Disorder.Internal medicine (Tokyo, Japan) · 2026Article
- Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy.Molecular neurodegeneration · 2024Article
- Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum.Brain communications · 2024Article
- Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.Brain communications · 2024Article
- An Update on Apraxia of Speech.Current neurology and neuroscience reports · 2023Review
- Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy.Parkinsonism & related disorders · 2023Article
- Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundProgressive supranuclear palsy (PSP) may present as a speech/language disorder (PSP-SL).
objectiveWe assessed pathological correlates of patients with PSP-SL who retained the suggestive of PSP-SL (s.o. PSP-SL) diagnosis versus those who progressed to possible/probable (poss./prob.) PSP.
methodsThirty-four prospectively recruited patient with s.o. PSP-SL completed comprehensive speech/language and neurological assessments longitudinally, died, and underwent autopsy.
resultsTwelve patients (35%) evolved to poss./prob PSP, while 22 (65%) remained as s.o. PSP-SL. Pathological diagnoses differed across the groups (P = 0.025). Patients with s.o. PSP-SL had four different neuropathologies (corticobasal degeneration [59%], PSP [13%], Pick's disease [14%], and frontotemporal lobar degeneration with TDP-43 [14%]), while all patients with poss./prob. PSP had a 4R-tauopathy (PSP [67%] and corticobasal degeneration [33%]). Development of poss./prob. PSP increased the chance of having PSP pathology by 2.38 times.
conclusionsPSP-SL is associated with heterogenous pathologies. Evolution of PSP-SL into poss./prob. PSP is more predictive of underlying PSP pathology than s.o. PSP-SL. © 2021 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.